All In Biotech

NDA 020717 · Nuvo Pharms

Provigil

Modafinil · Oral · Sympathomimetic-like Agent

NovelOrphan

Last checked: Nov 20, 2026Latest source record: Jan 15, 2015 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1998

Dec 24, 1998

Approved uses

2

Original approval plus efficacy supplements

Registered trials

214

53 Phase 3, 7 recruiting

FAERS reports

32,343

18,783 serious, 1,083 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 16, 2026.

PROVIGIL is indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea (OSA), or shift work disorder (SWD). Limitations of Use In OSA, PROVIGIL is indicated to treat excessive sleepiness and not as treatment for the underlying obstruction. If continuous positive airway pressure (CPAP) is the treatment of choice for a patient, a maximal effort to treat with CPAP for an adequate period of time should be made prior to initiating and during treatment with PROVIGIL for excessive sleepiness. PROVIGIL is indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea (OSA), or shift work disorder (SWD). ( 1 ) Limitations of Use In OSA, PROVIGIL is indicated to treat excessive sleepiness and not as treatment for the underlying obstruction.

Mechanism: The mechanism(s) through which modafinil promotes wakefulness is unknown. Modafinil has wake-promoting actions similar to sympathomimetic agents including amphetamine and methylphenidate, although the pharmacologic profile is not identical to that of the sympathomimetic amines. Modafinil-induced wakefulness can be attenuated by the α1-adrenergic receptor antagonist, prazosin; however, modafinil is inactive in other in vitro assay systems known to be responsive to α-adrenergic agonists such as the rat vas deferens preparation. Modafinil is not a direct- or indirect-acting dopamine receptor...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • PROVIGIL · MODAFINIL 200MG · TABLET, ORAL · Prescription · TE AB
  • PROVIGIL · MODAFINIL 100MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Modafinil" as an intervention, any sponsor and status, largest first.

All 214 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue2,978
  • nausea2,286
  • drug ineffective2,177
  • headache1,894
  • fall1,807
  • depression1,631
  • anxiety1,523
  • somnolence1,438
  • dizziness1,426
  • pain1,306
  • insomnia1,169
  • condition aggravated1,139

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004332
2005474
2006441
2007570
2008787
2009706
2010781
2011975
20121,009
2013801
20141,045
20152,421
20165,872
20172,523
20182,558
20192,338
20201,880
20211,267
20221,338
20231,328
20241,274
2025962
2026661

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Provigil (Modafinil)

2024 spending

$13.2M

Beneficiaries

494

2,880 claims

Per beneficiary

$26,748

$72.95 per unit

View as table
YearSpending
2020$17,518,344
2021$16,596,906
2022$14,549,020
2023$13,163,337
2024$13,213,729

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 529 on PubMed

Sponsor: Nuvo Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.